Targeting ALDOA Lactylation Reverses Vascular Remodeling in Pulmonary Hypertension by Disrupting Actin Polymerization and YAP Activation
Circulation · 03.11.2026
DOI: 10.1161/circulationaha.125.078300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, online erschienen am 03.11.2026. Verfasst von Xiaoxun Huang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology (X.H., J.Z., Q.Z., X.Z., Q.L.), Shanghai Jiao Tong University, China. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Maladaptive vascular remodeling is a hallmark of pulmonary hypertension (PH), and therapeutic strategies directly targeting the pathological activity of smooth muscle cells remain limited. Metabolic and epigenetic dysregulation are established drivers of PH, and lysine lactylation has emerged as a novel posttranslational modification implicated in diverse diseases; however, its direct contribution to PH progression remains undefined. METHODS: Integrated lactylomic and proteomic profiling was performed in hypoxic human pulmonary arterial smooth muscle cells. The functional role of ALDOA (aldolase A) lactylation at lysine 42 (K42) was assessed using site-specific mutant virus and smooth muscle cell-specific inducible ALDOA knockout mice in 2 established PH models: SU5416+hypoxia in mice and monocrotaline in rats. RESULTS: We identified ALDOA as a prominent lactylation target in hypoxic pulmonary arterial smooth muscle cells, with K42 lactylation consistently elevated in primary pulmonary arterial smooth muscle cells derived from PH rodent models and human PH tissues. Mechanistically, AARS1 (alanyl-tRNA synthetase 1)-mediated ALDOA K42 lactylation enhanced its binding to γ-actin, independent of glycolytic activity. This lactylation-enhanced interaction promoted F-actin polymerization and activated YAP (Yes-associated protein) signaling via LATS1 (large tumor suppressor kinase 1) inhibition, thereby driving pulmonary arterial smooth muscle cell proliferation and phenotypic switching. Moreover, YAP/TEAD4 (TEA domain transcription factor 4)-mediated transcriptional upregulation of AARS1 established a positive feedback loop reinforcing ALDOA K42 lactylation under hypoxia. In vivo, ALDOA inducible knockout or reconstitution with the lactylation-deficient K42R (lysine 42 mutant to arginine) mutant attenuated experimental PH progression, with suppressed F-actin/YAP activation and reduced vascular remodeling. Furthermore, competitive inhibition of lactylation through β‑alanine reduced ALDOA K42 lactylation and ameliorated vascular remodeling in ALDOA-overexpressing rodent PH models. Translationally, pharmacological disruption of the ALDOA/γ-actin interaction by raltegravir suppressed cytoskeletal reorganization and YAP signaling, mitigating PH progression in both mouse and rat models. CONCLUSIONS: AARS1-mediated ALDOA K42 lactylation drives pulmonary vascular remodeling through a mechanism independent of ALDOA’s catalytic activity, promoting F-actin polymerization and YAP activation. Precision targeting of this modification selectively inhibits pathological signaling while preserving metabolic homeostasis, highlighting a translational potential for precision intervention in PH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology (X.H., J.Z., Q.Z., X.Z., Q.L.), Shanghai Jiao Tong University, China.
- Precision Research Center for Refractory Diseases, Shanghai Jiao Tong University Pioneer Research Institute for Molecular and Cell Therapies (M.L., Z.S., Y.L., S. Li, Z.D., D.K.), Shanghai Jiao Tong University, China.
- Shanghai General Hospital, School of Medicine, State Key Laboratory of Innovative Immunotherapy, School of Pharmaceutical Sciences (M.L., Z.S., Y.L., S. Li, Z.D., D.K.), Shanghai Jiao Tong University, China.
- Guangzhou Institute of Respiratory Health (J.B., S. Liang, H.T.), First Affiliated Hospital of Guangzhou Medical University, China.
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangdong Key Laboratory of Vascular Disease (H.F., K.Y.), First Affiliat…
- Department of Infectious Diseases (J.L.), Second Xiangya Hospital of Central South University, Changsha, China.
ORCID-Profile: Xiaoxun Huang, Minghui Lin, Huazhuo Feng, Zhao Sha, Tongyu Peng, Yicheng Lv, Shengli Li, Tongqi Li, Shuxin Liang, Kai Yang, Haiyang Tang, Zhu Zhang, Yuhu He, Deping Kong
Zitieren
APA
Huang, X., Zhang, J., Zeng, Q., Lin, M., Bai, J., Feng, H., Liu, J., Sha, Z., Peng, T., Lv, Y., Zhang, X., Li, S., Li, T., Qu, J., Shao, S., Liu, Q., Liang, S., Yang, K., Tang, H., …, & Kong, D. (2026). Targeting ALDOA Lactylation Reverses Vascular Remodeling in Pulmonary Hypertension by Disrupting Actin Polymerization and YAP Activation. Circulation. https://doi.org/10.1161/circulationaha.125.078300
Vancouver
Huang X, Zhang J, Zeng Q, Lin M, Bai J, Feng H, et al. Targeting ALDOA Lactylation Reverses Vascular Remodeling in Pulmonary Hypertension by Disrupting Actin Polymerization and YAP Activation. Circulation. 2026. doi:10.1161/circulationaha.125.078300
BibTeX
@article{Huang2026,
author = {Huang, Xiaoxun and Zhang, Jincheng and Zeng, Qingye and Lin, Minghui and Bai, June and Feng, Huazhuo and Liu, Jing and Sha, Zhao and Peng, Tongyu and Lv, Yicheng and Zhang, Xiaoyu and Li, Shengli and Li, Tongqi and Qu, Jin and Shao, Shuai and Liu, Qian and Liang, Shuxin and Yang, Kai and Tang, Haiyang and Zhang, Zhu and He, Yuhu and Duan, Zhenzhen and Kong, Deping},
title = {Targeting ALDOA Lactylation Reverses Vascular Remodeling in Pulmonary Hypertension by Disrupting Actin Polymerization and YAP Activation},
journal = {Circulation},
year = {2026},
doi = {10.1161/circulationaha.125.078300}
}
EUVIMED